Abilify Withdrawal & Tapering Guide
aripiprazole
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis. Suicidality risk in children, adolescents, and young adults (for MDD adjunct indication).
In short
Abilify (aripiprazole) is an Atypical Antipsychotic with a half-life of 75–94 hours. Very long half-life. It is also sold as Abilify Maintena, Aristada.
- Class
- Atypical Antipsychotic
- Half-life
- 75–94 hours
- Common doses
- 2mg, 5mg, 10mg, 15mg, 20mg, 30mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Aripiprazole is an atypical antipsychotic with a unique mechanism as a partial agonist at dopamine D2 receptors. It is approved for schizophrenia, bipolar I disorder, adjunctive treatment of MDD, irritability in autism, and Tourette disorder.
2mg, 5mg, 10mg, 15mg, 20mg, 30mg
Tablets: 2mg, 5mg, 10mg, 15mg, 20mg, 30mg; Orally disintegrating tablets: 10mg, 15mg; Oral solution: 1mg/mL; Intramuscular injection: 9.75mg/1.3mL; Extended-release injection (Abilify Maintena): 300mg, 400mg
Category C (risk cannot be ruled out)
Mechanism of Action
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and antagonist at serotonin 5-HT2A receptors. This unique "dopamine stabilizer" profile means it can act as a functional antagonist in hyperdopaminergic states and a functional agonist in hypodopaminergic states.
Taper Notes
Very long half-life. Liquid formulation (1mg/mL) available. Often used as adjunct to antidepressants.
Hyperbolic Tapering Guidance
Long half-life provides some buffering. Oral solution (1mg/mL) allows precise reductions. Reduce gradually despite long half-life.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- CYP2D6 inhibitors (fluoxetine, paroxetine) increase aripiprazole levels — reduce aripiprazole dose by 50%
- CYP3A4 inhibitors (ketoconazole, itraconazole) increase aripiprazole levels — reduce dose by 50%
- CYP3A4 inducers (carbamazepine, rifampin) decrease aripiprazole levels — double dose when co-administered
Food Interactions
- Food does not affect absorption
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to aripiprazole
Toxicity
Akathisia is the most common dose-limiting side effect. Less metabolic burden than other atypicals (lower weight gain, lipid changes). Compulsive behaviors (gambling, eating, shopping) reported. NMS and tardive dyskinesia rare.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~87%. Tmax 3–5 hours. Food does not significantly affect absorption.
~4.9 L/kg
Hepatic via CYP3A4 and CYP2D6 to the active metabolite dehydro-aripiprazole, which has similar D2 receptor affinity. Dehydro-aripiprazole represents ~40% of parent drug AUC in plasma.
Fecal (~55%) and renal (~25%). Less than 1% excreted unchanged in urine.
>99% (primarily albumin)
~3.5 mL/min/kg
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Atypical Antipsychotic medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 10 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (10 mg start) |
|---|---|---|
| Start | 100% | 10 mg |
| Step 1 | 90% | 9 mg |
| Step 2 | 81% | 8.1 mg |
| Step 3 | 73% | 7.29 mg |
| Step 4 | 66% | 6.56 mg |
| Step 5 | 59% | 5.9 mg |
| Step 6 | 53% | 5.31 mg |
| Step 7 | 48% | 4.78 mg |
| Step 8 | 43% | 4.3 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Abilify, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Abilify
What are the withdrawal symptoms of Abilify (aripiprazole)?
Common withdrawal symptoms of Abilify (aripiprazole) include: insomnia, anxiety, nausea, irritability, akathisia. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Abilify (aripiprazole)?
Very long half-life. Liquid formulation (1mg/mL) available. Often used as adjunct to antidepressants. Long half-life provides some buffering. Oral solution (1mg/mL) allows precise reductions. Reduce gradually despite long half-life.
Can I stop Abilify cold turkey?
Stopping Abilify abruptly is not recommended. Its half-life is 75–94 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Abilify stay in your system?
Abilify (aripiprazole) has a half-life of 75–94 hours. A drug is mostly cleared after about five half-lives, so Abilify is largely out of the body roughly 2 to 3 weeks after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Recent discussions about Abilify
What members tapering Abilify are asking and reporting right now. Personal experience, not medical advice.
- Abilify Tapering ThreadThis is the forum for everyone tapering Abilify. When you log a check-in in My Taper, it will appear here. That way you can see how others on the same medication are…Based · 8 months ago
- How to taper several drugs?Is there a consensus on how to taper when your on multiple drugs? Assuming that I taper one at a time do you: (a) Taper until fully off one then over to the next (b)…Vic247 · 3 days ago · 4 replies
- Maintena Abilify ReductionIt is very likely I will finally reduce my monthly dose of Maintena Abilify (for those who don't know it is a long acting injection that last a month) next week. The…The Blue Dragonfly · 11 days ago · 2 replies
- Personal Abilify taper plan 2026So I came up with a strategy how to reduce dosage of Abilify before doing final Olanzapine taper. Been on 25mg Abilify for 9 years. Between reductions are 6 week hold…Adam · 18 days ago · 3 replies
- Staying at 300mg AbilifyIn the end, I didn't lower the intramuscular Abilify injection this month; I stayed at 300 mg of Maintena. However, I saw that I could perhaps lower it to 200 mg and…The Blue Dragonfly · 3 months ago · 13 replies
Sources & References
Abilify (aripiprazole) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.